Brazilian butt lift ads which promised ‘perfect peachy look' banned
Adverts which promoted liquid Brazilian butt lifts in Manchester have been banned for trivialising the risks of the procedures.
Facebook and Instagram ads also exploited women's insecurities around body image, the Advertising Standards Authority said.
The regulator has banned adverts for six providers - Beautyjenics, Bomb Doll Aesthetics, Ccskinlondondubai, EME Aesthetics, Dr Ducu and Rejuvenate Clinics.
READ MORE: 'It's like a lake underneath where they are going to build it'
READ MORE: Mum whose 'terrified' son was 'grabbed by police officer' in chaotic footage hits out
They said each of the Facebook and Instagram ads irresponsibly pressured consumers into booking the treatments.
A liquid BBL - also known as a non-surgical BBL - involves the injection of a dermal filler into the bottom to enhance its volume and shape.
The paid-for Facebook ad for Beautyjenics, seen in October, read: 'Bringing our liquid BBL to the North … Manchester … Limited space available 14th-16th October … Don't miss this exclusive opportunity to get that perfect peachy look!'
The ASA said guidance from the Joint Council for Cosmetic Procedures said liquid BBLs are considered to be surgical procedures, which carry a level of risk.
The watchdog said: 'Undertaking cosmetic surgery should have been portrayed as a decision that required time and thought from consumers before proceeding, because of the risks involved.'
It added: 'We considered that consumers could have been rushed into making a decision to have cosmetic surgery without taking sufficient time to consider the consequences.
'Because the ad created a sense of undue urgency to book a cosmetic procedure quickly, we considered that it had not been prepared in a socially responsible manner and therefore breached the Code.'
The ASA further found that the ad risked exploiting women's insecurities around body image, particularly those with insecurities relating to their body shape, concluding that it was irresponsible.
Bomb Doll Aesthetics, Ccskinlondondubai, EME Aesthetics, Dr Ducu and Rejuvenate Clinics offered time-limited Black Friday deals, which the ASA said pressured consumers into booking the procedures.
Beautyjenics, Bomb Doll Aesthetics and Ccskinlondondubai did not respond to the ASA's inquiries.
Rejuvenate Clinics said it has reviewed ASA guidance and will remove all references to time-limited offers and state in ads that the surgery is carried out by a medical professional with ultrasound to minimise risks and enhance safety.
EME Aesthetics said all its clients are given a full consultation and are under no obligation to book any procedures, and it therefore considers that its ad had not pressured consumers or trivialised the risks of cosmetic procedures.
Dr Ducu said it will ensure it follows the ASA's rules and guidance, that the time-limited Black Friday offer was intended to provide consumers with an opportunity to access the company's services at a discounted rate, and it always encourages consumers to make informed decisions without pressure.
The ASA said: 'In each case, we found that the ads irresponsibly pressured consumers into booking, and trivialised the risks of, liquid BBLs or exploited women's insecurities surrounding body image.
'These rulings form part of a wider piece of work on ads for liquid BBLs, identified for investigation following intelligence-gathering by our Active Ad Monitoring system, which uses AI to proactively search for online ads that might break the rules.'
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
4 hours ago
- Yahoo
Older people ‘bombarded' with ads for funerals, care homes and mobility aids
Older people say they are being 'bombarded' by campaigns for funeral services, care homes and mobility aids by 'out-of-touch' mainstream advertising, a study has found. The Advertising Standards Authority (ASA) said more than a third of the UK population (35%) agreed that older people tended to be negatively stereotyped in ads, with other depictions such as forgetfulness, frailty or not being able to use technology also seen as potentially offensive. While not offensive, depictions such as older people always being wealthy or grumpy, or ads that showed them doing extreme and unrealistic activities, were found to be cliched and irritating. Almost half (49%) said ads using humour at the expense of older people were likely to cause offence. Some 44% believed that older people were either underrepresented or not represented at all in ads, particularly in categories like fashion, beauty, technology and household goods. Respondents also raised concerns about how ads were targeted, saying they felt 'bombarded' by promotions for end-of-life services such as funerals or cremations, life insurance and care homes. The ASA's report, based on focus groups and a survey of 4,000 UK adults, said older people were not only living longer but also continuing to lead full, active lives, contributing to workplaces, families, communities and the economy for longer. However, many of those surveyed said that advertising too often painted a 'very different and outdated picture'. The watchdog said ads showing older people as lonely, purposeless or powerless could be harmful – especially for those aged 75 and over, for whom these portrayals reinforced fears about ageing and social isolation. It also flagged beauty ads that suggested ageing must be 'fought' as potentially harmful. In particular, women aged 65 and over recognised the potential for these ads to cause harm to the self-esteem of women of all ages. The ASA said the findings suggested the ad industry may be 'out of touch' with the reality of ageing. Instead, the public wanted advertising to focus on individuals rather than their age, and portray a diverse range of later-life experiences. The ASA said: 'When ads show older people as vibrant, capable and real, they help rewrite the story of ageing and how we perceive older generations. 'Not only this, but older people represent a significant market with substantial spending power, making them a vital audience for brands that want to stay relevant. 'While we're not currently proposing any new rules, we're hoping that by sharing this research, advertisers will understand how some portrayals of older people are landing with the public today – and where there may be unintended consequences.' Kam Atwal, research lead at the ASA, said: 'As a society, we're living longer, richer and more varied lives. 'Our research reveals that some of today's portrayals of older people in advertising are not being received positively, and that the public want ads to better reflect the varied lives older people lead today. 'This is a real opportunity for brands to embrace the true diversity of later life and take a leading role in challenging outdated perceptions.' Harriet Bailiss, co-head of the Age Without Limits campaign, run by the Centre for Ageing Better charity, said: 'We really welcome this excellent report from the ASA. 'We live in a society where ageism is the most common form of discrimination. We should all want that to end and we all have a role to play in making that happen. 'Advertising has such a powerful influence on society and can help bring about that change and be a force for good, as it has already been for changing other outdated perceptions.'
Newsweek
13 hours ago
- Newsweek
Scorpion Venom Could Help Treat Breast Cancer
Based on facts, either observed and verified firsthand by the reporter, or reported and verified from knowledgeable sources. Newsweek AI is in beta. Translations may contain inaccuracies—please refer to the original content. A venomous creature from the Amazon rainforest may hold the key to fighting one of the deadliest cancers affecting women today. According to the American Cancer Society, skin cancers aside, breast cancer is the most common cancer among women in the U.S.—accounting for about 30% of all new female cancer cases annually, with an estimated 42,170 women expected to die from it in 2025. Brazilian scientists have discovered that the venom of the Brotheas amazonicus scorpion contains a molecule that kills breast cancer cells in a way similar to chemotherapy, according to a groundbreaking study by researchers in Brazil. "Through bioprospecting, we were able to identify a molecule in the species of this Amazonian scorpion that is similar to that found in the venoms of other scorpions and that acts against breast cancer cells," said Eliane Candiani Arantes, a professor at the University of São Paulo and the project's coordinator. A stock image of a scorpion in the laboratory. A stock image of a scorpion in the laboratory. Sinhyu/iStock/Getty Images Plus The molecule in question, called BamazScplp1, is a type of peptide—a short chain of amino acids—that showed cancer-fighting properties when tested in the lab. It worka similarly to paclitaxel, a standard chemotherapy drug, by inducing necrosis, or uncontrolled cell death, in breast cancer cells. Unlike some other cell-killing processes that are regulated by the body, necrosis causes the cancer cells to burst and die—a tactic that has also been observed in other venom-based compounds. What Is Bioprospecting? Bioprospecting is the process of searching for useful compounds in nature, especially from plants, animals, and microorganisms. In this case, the team explored scorpion venom for potential bioactive molecules—substances that affect living tissues in a beneficial way, such as fighting infections or cancer. Turning Venom into Medicine—Without the Scorpions The researchers aren't milking scorpions for their venom at scale. Instead, they are using a process called heterologous expression, which means inserting the gene that produces a particular protein into another organism—often yeast or bacteria—so it can be produced in large quantities in the lab. "We also intend to obtain these molecules through heterologous expression," Arantes said, referring to BamazScplp1 and other promising compounds. One such host organism is Pichia pastoris, a species of yeast originally isolated in France in 1950. It's commonly used in biotechnology to manufacture proteins that would otherwise be difficult to source naturally. "Our idea now is to obtain this serine protease through heterologous expression [in a fragment or complete gene from a host organism that doesn't have it naturally] in Pichia pastoris," she added. The "Super Glue" Made from Snake Venom This isn't the first time researchers in Brazil have turned to venom for medical innovation. At the Center for the Study of Venoms and Venomous Animals (CEVAP), scientists developed a patented product called fibrin sealant—a kind of biological glue made by combining serinoproteinase (an enzyme found in snake venom) with cryoprecipitate, a component derived from the blood of buffalo, cattle, or sheep and is rich in fibrinogen, a protein essential for blood clotting. When mixed, the two form a fibrin network, mimicking the body's natural healing process. This sealant has been studied for uses like nerve repair, bone injury treatment and even helping restore movement after spinal cord injuries. It is currently in phase three clinical trials, the last stage before a drug can be considered for approval and widespread use. "This growth factor favors the formation of new vessels. If we combine it with colinein-1, we can create an improved fibrin sealant compared to the one being developed at CEVAP, with the possibility of expanding the industrial scale, since it can be obtained through heterologous expression," Arantes said. A Bigger Push Toward Biopharmaceutical Innovation All of this work is being carried out as part of the Center for Translational Science and Development of Biopharmaceuticals (CTS), a program aimed at turning biological discoveries into practical medical treatments. The CTS is part of a broader push by FAPESP, a public foundation in Brazil that funds scientific research. Their strategy isn't limited to scorpion venom. The team has also worked with rattlesnake proteins, including a compound called cholinein-1, and is developing another bioactive substance known as CdtVEGF, which promotes the growth of blood vessels—a potentially valuable tool in tissue regeneration. What Comes Next? The discovery of BamazScplp1 is still in the early stages. The results were shared at FAPESP Week France, a scientific conference held from June 10 to 12 in Toulouse, southern France. But the findings highlight the growing interest in nature-based compounds and how they might work alongside or even replace traditional treatments like chemotherapy. If further tests confirm its effectiveness and safety, the molecule from the scorpion could someday be developed into a new kind of anti-cancer drug, offering patients more options and possibly fewer side effects. Do you have a tip on a health story that Newsweek should be covering? Do you have a question about breast cancer? Let us know via health@
Yahoo
19 hours ago
- Yahoo
Brazil poised to declare itself bird flu 'free,' state official says
By Ana Mano, Roberto Samora and Debora Ely SAO PAULO (Reuters) -Brazil is ready to declare the country free of the bird flu virus on commercial flocks, Edivilson Brum, the head of Rio Grande do Sul state's agriculture department, said on Wednesday in a statement. The 28-day countdown for reclaiming the country's disease-free status began on May 22 following the complete disinfection of the farm where Brazil's only commercial flock outbreak was detected last month. Under existing trade protocols, China and other importers banned chicken imports from Brazil, the world's largest exporter, pending measures to control the disease on commercial facilities. "We have fulfilled all the steps provided for in the health protocols so that Brazil can once again declare itself an influenza-free country to the World Organization for Animal Health," Brum said, referring to the highly pathogenic avian influenza virus (HPAI). The Brazilian ministry of agriculture did not have an immediate comment. Brazil's first outbreak hit a chicken breeder farm in Brazil's southernmost state of Rio Grande do Sul last month, triggering trade bans that may now be reversed with the regaining of the disease-free status. Reclaiming Brazil's status as free HPAI is not automatic and must be confirmed by the World Organization for Animal Health (WOAH), according to guidelines from the body.
